Retatrutide 20mg + Tirzepatide 40mg Blend
Also known as Triple plus dual incretin blend
Combination incretin research blend (10 mL vial)
A combined vial pairing a triple receptor agonist with a dual incretin agonist in a single reconstituted solution.
How it works
Combines GIP, GLP-1 and glucagon receptor activity from retatrutide with the GIP and GLP-1 profile of tirzepatide, so total incretin receptor occupancy per unit volume is higher than either compound alone.
What research has shown
No trials study this exact blend. Evidence comes from the separate retatrutide and tirzepatide programs, which report weight reductions of roughly 24% and 21% respectively at their highest doses.
Reported ranges in the literature
Low end
Volume equivalent to about 1 mg retatrutide plus 2 mg tirzepatide weekly
Optimal
Volume equivalent to about 4 mg retatrutide plus 8 mg tirzepatide weekly
High end
Volume equivalent to about 6 mg retatrutide plus 12 mg tirzepatide weekly
Frequency reported in the literature: Once weekly. Note: Blend vials carry two active concentrations, so calculate each component separately.
Protocol duration and pairing
Typical study duration
No blend-specific trial exists; the underlying single-agent programs run 36 to 48 weeks.
Best paired with
Because the blend already stacks two incretin agents, additional incretin compounds are redundant in the literature.
Research use only
All content on this page is general reference information for laboratory research contexts. It is not medical advice, is not intended to direct human use, and does not replace guidance from a licensed healthcare professional. Not for human consumption. Must be 18+.